An Open-label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative (HER2-) Advanced Breast Cancer (aBC) With no Prior Hormonal Therapy for Advanced Disease
The purpose of this Phase IIIb study is to collect additional safety and efficacy data for the combination of ribociclib + letrozole in men and postmenopausal women with HR+HER2- advanced breast cancer.
Key Inclusion Criteria:
Hormone-Positive, HER2-Negative, metastatic breast cancer
Men and post-menopausal women
Able to swallow tablets
Peter Jiang, M.D., Ph.D.
- Providence Regional Cancer Partnership - Everett